Lb Pharmaceuticals (LBRX) Non-Current Assets (2024 - 2026)

Lb Pharmaceuticals' Non-Current Assets history runs 3 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• On a quarterly basis, Non-Current Assets changed N/A year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $17.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.5 million, down 3.29% from the prior year.
• Non-Current Assets fell to $4.4 million in Q1 2026 per LBRX's latest filing, from $4.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $4.7 million in Q4 2024 and bottomed at $4.3 million in Q3 2025.
• The 3-year median for Non-Current Assets is $4.5 million (2025), against an average of $4.5 million.
• Biggest YoY gain for Non-Current Assets was 3.29% in 2025; the steepest drop was 3.29% in 2025.
• Year by year, Non-Current Assets stood at $4.7 million in 2024, then declined by 3.29% to $4.5 million in 2025, then decreased by 2.09% to $4.4 million in 2026.
• Per Business Quant, the three latest LBRX Non-Current Assets figures stand at $4.4 million (Q1 2026), $4.5 million (Q4 2025), and $4.3 million (Q3 2025).